High-risk Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for High-risk Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 1]
Phase 1 trial evaluating the safety of a multi-agent regimen (CDX-1401, Poly ICLC, Decitabine, and Nivolumab) in patients with myelodysplast…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating liposome-encapsulated daunorubicin-cytarabine (CPX-351) in combination with gemtuzumab ozogamicin for relapsed or r…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome [Phase 2]
This Phase 2 clinical trial investigates the combination of azacitidine and enasidenib for IDH2-mutant myelodysplastic syndrome and is curre…
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML [Phase 2]
Clinical trial update on RVU120 for relapsed/refractory acute myeloid leukemia in a Phase 2 study. The trial is currently active but not rec…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating donor natural killer cells and donor stem cell transplant in high-risk myeloid malignancies; completed w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating daratumumab in relapsed or high-risk myeloid malignancies (high-risk myelodysplastic syndrome and recurrent/refract…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating treatments to improve outcomes for adults with acute myeloid leukemia and high-risk myelodysplastic sy…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes [Phase 2]
Phase 2 clinical trial evaluating bemcentinib for myelodysplastic syndromes and related conditions has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS [Phase 2]
Phase 2 randomized trial comparing azacitidine alone versus azacitidine with vorinostat in patients with acute myeloid leukemia or high-risk…
-
CLINICAL_TRIALS trial_result · 2018-05-30Clinical Trial Update: Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 trial of omacetaxine with low-dose cytarabine in older patients with acute myeloid leukemia and high-risk myelodysplastic syndrome h…
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias [Phase 1]
Phase 1 study of TH-302 (evofosfamide), a hypoxia-activated prodrug, in patients with advanced leukemias has been completed, with evaluation…
-
CLINICAL_TRIALS trial_result · 2013-09-09Clinical Trial Update: A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia [Phase 1]
A Phase 1 trial of PD-0332991 (palbociclib) followed by cytarabine and mitoxantrone in adults with relapsed or refractory acute leukemia and…